UIP Chosen as Vendor for NCATS Drug Product Development, Manufacture, and Stability Studies

August 07, 2017

The University of Iowa Pharmaceuticals (UIP) has been chosen as a vendor for the National Center for Advancing Translational Sciences (NCATS) contract, “CRO Support for NCATS Drug Product Development, Manufacture, and Stability Studies.”

NCATS at the National Institutes of Health studies translation on a system-wide level as a scientific and operational problem to accelerate the development of treatments and preventive strategies for a wide range of diseases. Within NCATS, the Division of Pre-Clinical Innovation (DPI) plans, conducts, and uses both internal and contract resources to advance collaborative research projects across the pre-clinical phases of the translational science spectrum.

As a vendor of NCATS, UIP will support the development, manufacturing, and stability studies of dosage forms of experimental therapeutics. The UIP application for this contract also included faculty from the UI College of Pharmacy that participate in the UIP Development Consortium (UIPDC). UIPDC is a formal connection between UIP and faculty in the College of Pharmacy where faculty can work with UIP and/or their students on pre-clinical drug development activities.

UIP is the largest and most experienced university-affiliated FDA-registered pharmaceutical manufacturing facility in the United States offering both sterile and non-sterile dosage forms. The organization has been providing GMP drug product services from pre-clinical to commercial since July 1974.

This project has been funded in whole or in part with Federal funds from the National Center for Advancing Translational Sciences, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN271201700019I.